Kingsview Wealth Management LLC Purchases 953 Shares of Danaher Co. (NYSE:DHR)

Kingsview Wealth Management LLC boosted its position in Danaher Co. (NYSE:DHR) by 2.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 38,105 shares of the conglomerate’s stock after acquiring an additional 953 shares during the period. Kingsview Wealth Management LLC’s holdings in Danaher were worth $10,594,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher during the second quarter valued at about $25,000. nVerses Capital LLC bought a new stake in shares of Danaher during the second quarter valued at about $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher during the third quarter valued at about $40,000. MFA Wealth Advisors LLC bought a new stake in shares of Danaher during the second quarter valued at about $51,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Danaher during the second quarter valued at about $51,000. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 18.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock opened at $235.83 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market cap of $170.34 billion, a PE ratio of 45.01, a P/E/G ratio of 4.32 and a beta of 0.85. The business has a 50 day moving average of $258.15 and a 200 day moving average of $259.88. Danaher Co. has a 52 week low of $215.68 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.02 earnings per share. As a group, equities research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is presently 20.61%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DHR shares. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Monday, November 18th. Wells Fargo & Company initiated coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Robert W. Baird cut their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. TD Cowen boosted their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Finally, Evercore ISI boosted their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.